ISK Ltd is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers
ISK Ltd is a resident company of Johnson & Johnson Innovation – JLABS
18/04/2024Related Posts
-
Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations
26/10/2023 -
Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal
18/12/2022ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.
-
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
23/10/2022ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
-
Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors
17/02/2022The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
-
PHASE 1B/2A Clinical trial started
13/04/2021
